A recent retrospective study of HCM patients with COVID-19 concluded that HCM patients are at increased risk of hospitalization and death from a COVID-19 infection.
In particular, the study found that the following groups of HCM patients were at increased risk of adverse complications from COVID-19:
- patients with the obstructive form of HCM
- patients with left ventricular systolic dysfunction
- older patients
- patients who also have other high risk conditions for COVID-19 such as hypertension, diabetes, obesity or those who are smokers
Based on this data, the researchers suggest “the need for aggressive and systematic implementation of prophylactic measures for SARS-COV-2 in patients with inherited cardiac disease.”
At this time, such measures include vaccinations, masking, and therapeutic agents such as Paxlovid and monoclonal antibodies.